CSBR Champions Oncology, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 9月 11, 2026CSBR 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
CSBR 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
| 権利落ち日 | 分割 | タイプ |
|---|---|---|
| 2015年8月12日 | 1-for-12 | 逆 |
Champions Oncology, Inc. - Common Stock について Wikipediaからの企業概要
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
TumorGrafts
Champions TumorGrafts maintain the microenvironment surrounding the tumor and have been shown to have high correlation to the patient’s tumor. Due to this close resemblance to the human tumor, TumorGrafts are highly predictive of treatment outcomes in patients. Studies have shown the mouse avatars predict clinical benefit in 80% of patients. Approximately 450 TumorGrafts have been established as of April 2014.
TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. Champions has formed partnerships with multiple drug developers, including Teva and Pfizer.
The process
When a cancer patient undergoes surgery or biopsy, a living sample of the tumor is obtained and implanted into the mouse, creating a mouse avatar. Once the TumorGraft has successfully grown, the tumor is then propagated in a second generation of mice and tested against a panel of cancer drugs and drug combinations to help identify more accurately which treatment regimen is likely to be most effective in a specific patient. In this way, various drugs are tested on a live sample of the actual patient's tumor, rather than on the patient. This reduces the likelihood of treatment with ineffective drugs and their associated side effects, and it increases the likelihood of finding a treatment that will work against the patient's tumor. For patients whose tumors have also undergone molecular testing, such as next-generation sequencing, the selection of potential drugs is further guided by any and all applicable results. In the event the cancer progresses or recurs, Champions also banks, or stores, each successful TumorGraft for potential future patient use.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か?
| 指標 | 5年トレンド | CSBR | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E | -61.85年平均 ≈23.5 | ≈23.5 | · | · | |
| P/S (TTM) | 1.15年平均 ≈1.6 | ≈1.6 | 2.7 | 割安 | |
| 株価純資産倍率 (MRQ) | 17.75年平均 ≈7.7 | ≈7.7 | 1.8 | 割高 | |
| 株価FCF倍率 (TTM) | -11.25年平均 ≈14.8 | ≈14.8 | · | · | |
| 株価収益率(P/CF) (TTM) | -12.45年平均 ≈3.4 | ≈3.4 | · | · | |
| Price / Tangible Book (株価純資産倍率(P/TB)) | 19.05年平均 ≈19.7 | ≈19.7 | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | CSBR | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 営業利益率 (TTM) | -1.7%5年平均 ≈-3.4% | ≈-3.4% | -108.0% | トップクラス | |
| EBITDAマージン (TTM) | 0.55%5年平均 ≈-0.32% | ≈-0.32% | -108.0% | トップクラス | |
| 税引前利益率 (TTM) | -1.5%5年平均 ≈-3.3% | ≈-3.3% | -100.0% | トップクラス | |
| 純利益率 (TTM) | -1.9%5年平均 ≈-3.4% | ≈-3.4% | -105.8% | トップクラス | |
| ROA | -4.0%5年平均 ≈-5.1% | ≈-5.1% | -26.0% | トップクラス | |
| ROE | -30.5%5年平均 ≈92.6% | ≈92.6% | -34.9% | 同水準 | |
| ROIC | -36.6%5年平均 ≈72.5% | ≈72.5% | -38.6% | 同水準 |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | CSBR | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 流動比率 (MRQ) | 1.05年平均 ≈0.9 | ≈0.9 | 2.9 | 低流動性 | |
| Quick Ratio (クイックレシオ) | 0.95年平均 ≈0.8 | ≈0.8 | 1.4 | 低流動性 |
成長 収益、EPS、純利益の成長率:前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | CSBR | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益(前年比)) | 4.4%5年平均 ≈8.1% | ≈8.1% | · | · | |
| Revenue CAGR 3Y (収益(3年CAGR)) | 3.3%5年平均 ≈8.5% | ≈8.5% | · | · | |
| Revenue CAGR 5Y (収益(5年CAGR)) | 7.7% | · | · | · | |
| EPS CAGR 3Y (EPS年平均成長率 3年) | 102.1% | · | · | · | |
| Net Income CAGR 3Y (純利益年平均成長率 3年) | 104.7% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | CSBR | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 2.05年平均 ≈1.7 | ≈1.7 | 0.4 | トップクラス | |
| Receivables Turnover (売掛金回転率) | 4.95年平均 ≈5.7 | ≈5.7 | 5.0 | 同水準 | |
| Revenue / Employee (年間売上高 ÷ 従業員数(yfinanceの報告ヘッドカウント)。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$277.7K | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2027年3月31日 | 9月 10, 2026 | $-0.03 | $-0.01 | -194.1% |
| 2026年9月30日 | $-0.03 | $-0.01 | -194.1% | |
| 2026年6月30日 | $-0.05 | $-0.05 | 2.0% | |
| 2026年3月31日 | $-0.02 | $0.09 | -121.8% | |
| 2025年12月31日 | $0.02 | $0.01 | 96.1% | |
| 2025年9月30日 | $0.02 | $-0.01 | 296.1% | |
| 2025年6月30日 | $-0.07 | $-0.20 | 65.7% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Cost of Revenue | $31M | $28M | $29M | $30M | $24M | $21M | $17M | · | · | |
| R&D Expense | $9M | $7M | $10M | $12M | $9M | $7M | $6M | $5M | $4M | |
| SG&A Expense | $11M | $9M | $11M | $10M | $9M | $7M | $7M | $5M | $4M | |
| Operating Expenses | · | · | · | · | · | · | $34M | $27M | $22M | |
| Operating Income | $-1M | $5M | $-7M | $-5M | $607.0K | $366.0K | $-2M | $270.0K | $-1M | |
| Other Non-op | $211.0K | $73.0K | $48.0K | $-11.0K | $-24.0K | $71.0K | $-42.0K | $-39.0K | $-89.0K | |
| Pretax Income | $-929.0K | $5M | $-7M | $-5M | $583.0K | $437.0K | $-2M | $231.0K | $-1M | |
| Income Tax | $246.0K | $-75.0K | $-32.0K | $68.0K | $35.0K | $75.0K | $130.0K | $103.0K | $33.0K | |
| Net Income | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| EPS (Basic) | $-0.08 | $0.34 | $-0.54 | $-0.39 | $0.04 | $0.03 | $-0.18 | $0.01 | $-0.13 | |
| EPS (Diluted) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | |
| Shares (Basic) | 13,832,385 | 13,659,786 | 13,547,604 | 13,541,559 | 13,197,170 | 13,138,995 | 11,843,463 | 11,340,184 | 10,991,105 | |
| Shares (Diluted) | 13,832,385 | 14,266,781 | 13,547,604 | 13,541,559 | 14,159,799 | 14,573,561 | 11,843,463 | 14,096,117 | 10,991,105 | |
| EBITDA | $260.0K | $6M | $-6M | $-3M | $2M | $2M | $-978.0K | $876.0K | $-994.0K |
貸借対照表
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $10M | $3M | $10M | $9M | $5M | $8M | $3M | $856.0K | |
| Receivables | $13M | $11M | $10M | $8M | $10M | $7M | $5M | $4M | $4M | |
| Prepaid Expense | $1M | $1M | $1M | $1M | $1M | $957.0K | $385.0K | $308.0K | $287.0K | |
| Current Assets | $19M | $22M | $14M | $19M | $20M | $13M | $13M | $8M | $5M | |
| PP&E (Net) | · | · | · | · | $7M | $6M | $4M | $3M | $2M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $13M | $10M | $7M | $5M | $4M | |
| Accum. Depreciation | $13M | $12M | $10M | $9M | $6M | $4M | $3M | $2M | $1M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $670.0K | $669.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $185.0K | $15.0K | $15.0K | $15.0K | $128.0K | $128.0K | $116.0K | |
| Total Assets | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Accounts Payable | $7M | $4M | $6M | $5M | $3M | $2M | $3M | $3M | $2M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $1M | $569.0K | |
| Current Liabilities | $20M | $24M | $22M | $22M | $17M | $11M | $12M | $8M | $7M | |
| Capital Leases | $3M | $5M | $6M | $7M | $8M | $9M | $3M | $0 | $17.0K | |
| Other Non-current Liabilities | $7.0K | $85.0K | $401.0K | $551.0K | $391.0K | $181.0K | $178.0K | $151.0K | $151.0K | |
| Total Liabilities | $23M | $29M | $28M | $30M | $26M | $20M | $16M | $9M | $8M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $11.0K | |
| Retained Earnings | $-81M | $-80M | $-85M | $-77M | $-72M | $-73M | $-73M | $-71M | $-71M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $74.0K | $0 | · | · | $0 | $1M | |
| Stockholders' Equity | $4M | $4M | $-2M | $5M | $9M | $7M | $5M | $2M | $3.0K | |
| Liabilities + Equity | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Shares Outstanding | 13,886,826 | 13,897,503 | 13,714,099 | 13,558,650 | 13,522,441 | 13,414,066 | 12,726,728 | 11,619,538 | 11,003,228 |
キャッシュフロー
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $2M | $925.0K | $825.0K | $606.0K | $360.0K | |
| Stock-based Comp | $1M | $654.0K | $1M | $864.0K | $912.0K | $598.0K | $600.0K | $636.0K | $1M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-6M | $431.0K | $-2M | $6M | $4M | $-4M | $3M | $492.0K | $-1M | |
| Operating Cash Flow | $-4M | $7M | $-6M | $4M | $6M | $-2M | $3M | $2M | $-1M | |
| CapEx | $564.0K | $389.0K | $836.0K | $3M | $2M | $3M | $2M | $834.0K | $1M | |
| Investing Cash Flow | $-540.0K | $-389.0K | $-836.0K | $-3M | $-2M | $-3M | $-2M | $-834.0K | $-1M | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | · | $0 | $634.0K | $74.0K | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | $-634.0K | $-74.0K | · | · | · | · | $0 | |
| Financing Cash Flow | $99.0K | $170.0K | $-527.0K | $11.0K | $207.0K | $1M | $4M | $1M | $13.0K | |
| Net Change in Cash | $-5M | $7M | $-8M | $1M | $4M | $-4M | $5M | $2M | $-2M | |
| Taxes Paid | $242.0K | $43.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | $-5M | $7M | $-7M | $1M | $4M | $-5M | $685.0K | $1M | $-2M |
収益性
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% | 0.89% | · | 1.0% | · | |
| Net Margin | -2.0% | 8.3% | -14.5% | -9.9% | 1.1% | 0.88% | · | 0.47% | · | |
| Pretax Margin | -1.6% | 8.1% | -14.6% | -9.8% | 1.2% | 1.1% | · | 0.85% | · | |
| EBITDA Margin | 0.44% | 10.8% | -11.3% | -5.9% | 4.3% | 3.8% | · | 3.2% | · | |
| ROA | -4.0% | 16.1% | -24.1% | -15.3% | 1.7% | 1.5% | -12.5% | 1.3% | -18.6% | |
| ROE | -30.5% | 211.1% | 367.4% | -91.2% | 6.0% | 4.7% | -36.9% | 5.6% | -744.4% | |
| ROIC | -36.6% | 122.7% | 384.9% | -114.8% | 6.3% | 4.1% | -36.3% | 6.7% | -46165.5% |
流動性と支払能力
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 | 1.1 | 1.1 | 1.0 | 0.7 | |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 | 1.0 | 1.1 | 0.9 | 0.6 |
効率性
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.0 | 1.9 | 1.7 | 1.5 | 1.6 | 1.7 | · | 2.8 | · | |
| Receivables Turnover | 4.9 | 5.5 | 5.8 | 6.3 | 6.0 | 7.0 | · | 6.5 | · |
1株あたり
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $0.27 | $-0.14 | $0.34 | $0.67 | $0.55 | $0.42 | $0.19 | $0.00 | |
| Revenue / Share | $4.30 | $3.99 | $3.70 | $3.98 | $3.47 | $2.82 | · | $1.92 | · | |
| Cash Flow / Share | $-0.32 | $0.52 | $-0.45 | $0.29 | $0.46 | $-0.12 | $0.25 | $0.13 | · | |
| Cash / Share | $0.35 | $0.71 | $0.19 | $0.75 | $0.67 | $0.35 | $0.65 | $0.28 | $0.08 | |
| EPS (TTM) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 |
成長率
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.4% | 13.5% | -6.9% | 9.7% | 19.7% | 27.8% | · | · | · | |
| Revenue CAGR 3Y | 3.3% | 5.1% | 6.9% | 18.8% | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.7% | 12.1% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | · | 100.0% | · | · | · | · | |
| EPS CAGR 3Y | · | 102.1% | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | · | · | 51.4% | · | · | · | · | |
| Net Income CAGR 3Y | · | 104.7% | · | · | · | · | · | · | · |
バリュエーション(TTM)
| 指標 | トレンド | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Net Income TTM | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| Market Cap | $83M | $99M | $66M | $67M | $104M | $144M | $98M | $106M | $48M | |
| P/E | -74.5 | 21.7 | -9.0 | -12.6 | 192.0 | 536.5 | -42.9 | 908.0 | -33.4 | |
| P/S | 1.4 | 1.7 | 1.3 | 1.2 | 2.1 | 3.5 | 3.1 | 36.4 | 2.4 | |
| P/B | 21.0 | 26.1 | -34.6 | 14.4 | 11.4 | 19.4 | 18.5 | 47.1 | 15918.0 | |
| P / Tangible Book | 23.0 | 28.7 | · | 15.5 | 11.9 | 20.3 | 20.6 | · | · | |
| P / Cash Flow | -18.5 | 13.3 | -10.7 | 16.8 | 16.0 | -85.6 | 33.8 | 56.7 | -39.0 | |
| P / FCF | -16.4 | 14.1 | -9.4 | 60.6 | 25.2 | -29.0 | 143.4 | 102.6 | -19.5 | |
| Earnings Yield | -1.3% | 4.6% | -11.1% | -7.9% | 0.52% | 0.19% | -2.3% | 0.11% | -3.0% |
損益計算書
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $14M | $17M | $15M | $14M | $12M | $17M | $13M | $14M | $14M | $12M | $12M | $13M | $13M | $13M | $14M | |
| Cost of Revenue | $8M | $7M | $9M | $7M | $8M | $7M | $7M | $7M | $7M | $7M | $8M | $7M | $8M | $7M | $8M | $7M | |
| R&D Expense | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Operating Income | $-409.0K | $-522.0K | $-276.0K | $185.0K | $-527.0K | $-2M | $4M | $732.0K | $1M | $-272.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $7.0K | |
| Other Non-op | $-6.0K | $27.0K | $39.0K | $70.0K | $75.0K | $42.0K | $19.0K | $7.0K | $5.0K | $81.0K | $58.0K | $-105.0K | $14.0K | $-20.0K | $36.0K | $-9.0K | |
| Pretax Income | $-415.0K | $-495.0K | $-237.0K | $255.0K | $-452.0K | $-2M | $5M | $739.0K | $1M | $-191.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-2.0K | |
| Income Tax | $11.0K | $172.0K | $42.0K | $18.0K | $14.0K | $-130.0K | $23.0K | $11.0K | $21.0K | $-82.0K | $11.0K | $11.0K | $28.0K | $20.0K | $17.0K | $14.0K | |
| Net Income | $-426.0K | $-728.0K | $-279.0K | $268.0K | $-466.0K | $-2M | $4M | $728.0K | $1M | $-109.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-16.0K | |
| EPS (Basic) | $-0.03 | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.14 | $0.33 | $0.05 | $0.10 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | |
| EPS (Diluted) | · | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.12 | $0.31 | $0.05 | $0.09 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | |
| Shares (Basic) | 13,897,535 | · | 13,886,797 | 13,791,913 | 13,788,414 | · | 13,700,627 | 13,593,766 | 13,593,766 | · | 13,593,758 | 13,497,061 | 13,506,782 | · | 13,558,642 | 13,528,643 | |
| Shares (Diluted) | · | · | 13,886,797 | 14,457,837 | 13,788,414 | · | 14,364,904 | 14,016,953 | 14,042,379 | · | 13,593,758 | 13,497,061 | 13,506,782 | · | 13,558,642 | 13,528,643 | |
| EBITDA | $-95.0K | · | $65.0K | $542.0K | $-169.0K | · | $5M | $1M | $2M | · | $-2M | $-1M | $-2M | · | $-2M | $567.0K |
貸借対照表
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $5M | $7M | $9M | $10M | $10M | $3M | $3M | $3M | $3M | $4M | $6M | $5M | $10M | $12M | $11M | |
| Receivables | $14M | $13M | $12M | $12M | $9M | $11M | $16M | $10M | $9M | $10M | $8M | $8M | $9M | $8M | $8M | $9M | |
| Prepaid Expense | $1M | $1M | $991.0K | $1M | $1M | $1M | $713.0K | $860.0K | $1M | $1M | $835.0K | $780.0K | $1M | $1M | $661.0K | $834.0K | |
| Current Assets | $19M | $19M | $20M | $21M | $21M | $22M | $20M | $14M | $13M | $14M | $13M | $14M | $15M | $19M | $20M | $21M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8M | |
| PP&E (Gross) | $17M | $16M | $16M | $16M | $16M | $16M | $17M | $16M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $14M | |
| Accum. Depreciation | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $9M | $7M | $7M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | |
| Other Non-current Assets | $201.0K | $212.0K | $196.0K | $196.0K | $196.0K | $196.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $184.0K | $15.0K | $15.0K | $15.0K | |
| Total Assets | $33M | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | |
| Accounts Payable | $6M | $7M | $6M | $6M | $5M | $4M | $5M | $5M | $5M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $3M | $3M | $3M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $19M | $20M | $21M | $22M | $23M | $24M | $20M | $19M | $19M | $22M | $22M | $21M | $20M | $22M | $21M | $19M | |
| Capital Leases | $10M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | $8M | |
| Other Non-current Liabilities | $215.0K | $7.0K | $27.0K | $46.0K | $66.0K | $85.0K | $285.0K | $324.0K | $363.0K | $401.0K | $439.0K | $476.0K | $514.0K | $551.0K | $588.0K | $624.0K | |
| Total Liabilities | $29M | $23M | $24M | $26M | $27M | $29M | $25M | $25M | $25M | $28M | $29M | $28M | $28M | $30M | $29M | $27M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Retained Earnings | $-81M | $-81M | $-80M | $-80M | $-80M | $-80M | $-78M | $-83M | $-83M | $-85M | $-84M | $-82M | $-80M | $-77M | $-75M | $-72M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $676.0K | $74.0K | · | · | |
| Stockholders' Equity | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $681.0K | $-332.0K | $-2M | $-2M | $93.0K | $2M | $5M | $7M | $9M | |
| Liabilities + Equity | $33M | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | |
| Shares Outstanding | 13,918,569 | 13,886,826 | 13,886,826 | 13,886,326 | 13,788,421 | 13,777,170 | 13,705,570 | 13,698,903 | 13,593,766 | 13,593,766 | 13,593,766 | 13,593,766 | 13,484,110 | 13,544,228 | 13,558,650 | 13,558,650 |
キャッシュフロー
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $314.0K | $344.0K | $341.0K | $357.0K | $358.0K | $354.0K | $398.0K | $399.0K | $449.0K | $490.0K | $481.0K | $484.0K | $445.0K | $437.0K | $575.0K | $560.0K | |
| Stock-based Comp | $766.0K | $357.0K | $423.0K | $249.0K | $208.0K | $131.0K | $256.0K | $9.0K | $258.0K | $263.0K | $379.0K | $53.0K | $423.0K | $208.0K | $331.0K | $119.0K | |
| Other Non-cash | $-1M | · | · | · | $470.0K | · | · | · | $-2M | · | · | · | $-2M | · | · | · | |
| Operating Cash Flow | $-492.0K | $-2M | $-1M | $-2M | $600.0K | $7M | $490.0K | $-283.0K | $311.0K | $-2M | $-919.0K | $589.0K | $-4M | $-692.0K | $2M | $3M | |
| CapEx | $55.0K | $239.0K | $37.0K | $242.0K | $46.0K | $253.0K | $42.0K | $94.0K | $0 | $-3.0K | $18.0K | $79.0K | $668.0K | $760.0K | $754.0K | $604.0K | |
| Investing Cash Flow | $-55.0K | $-238.0K | $-14.0K | $-242.0K | $-46.0K | $-253.0K | $-42.0K | $-94.0K | $0 | $3.0K | $-18.0K | $-79.0K | $-668.0K | $-760.0K | $-754.0K | $-604.0K | |
| Stock Repurchased | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $32.0K | $602.0K | $74.0K | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $0 | · | · | · | $-602.0K | · | · | · | |
| Financing Cash Flow | $33.0K | $-19.0K | $-36.0K | $168.0K | $-14.0K | $-32.0K | $0 | $239.0K | $-37.0K | $-37.0K | $-108.0K | $134.0K | $-590.0K | $-75.0K | $0 | $86.0K | |
| Net Change in Cash | $-514.0K | $-2M | $-1M | $-2M | $540.0K | $7M | $448.0K | $-138.0K | $274.0K | $-2M | $-1M | $644.0K | $-5M | $-2M | $819.0K | $3M | |
| Free Cash Flow | $-547.0K | · | · | · | $554.0K | · | · | · | $311.0K | · | · | · | $-5M | · | · | · |
収益性
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2.7% | · | -1.7% | 1.2% | -3.8% | · | 26.4% | 5.4% | 9.4% | · | -21.4% | -16.9% | -20.3% | · | -19.2% | 0.05% | |
| Net Margin | -2.8% | · | -1.7% | 1.8% | -3.1% | · | 26.4% | 5.4% | 9.3% | · | -21.1% | -17.9% | -20.4% | · | -19.1% | -0.11% | |
| Pretax Margin | -2.7% | · | -1.4% | 1.7% | -3.2% | · | 26.5% | 5.5% | 9.5% | · | -21.0% | -17.8% | -20.2% | · | -19.0% | -0.01% | |
| EBITDA Margin | -0.62% | · | 0.39% | 3.6% | -1.2% | · | 28.7% | 8.4% | 12.6% | · | -17.4% | -12.7% | -16.8% | · | -14.7% | 4.0% | |
| ROA | -1.3% | · | -0.94% | 0.97% | -1.6% | · | 15.7% | 2.7% | 4.8% | · | -8.0% | -6.4% | -8.0% | · | -7.0% | -0.05% | |
| ROE | -11.5% | · | -5.7% | 11.1% | -27.5% | · | 263.6% | 188.1% | 167.2% | · | -101.1% | -44.7% | -47.1% | · | -29.9% | -0.19% | |
| ROIC | -10.8% | · | -7.6% | 4.1% | -15.5% | · | 81.8% | 105.9% | -394.0% | · | 125.8% | -2113.4% | -135.6% | · | -35.0% | 0.61% |
流動性と支払能力
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | · | 1.0 | 1.0 | 0.9 | · | 1.0 | 0.7 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 1.0 | 1.1 | |
| Quick Ratio | 1.0 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.9 | 1.1 |
効率性
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | |
| Receivables Turnover | 1.3 | · | 1.2 | 1.4 | 1.5 | · | 1.4 | 1.5 | 1.6 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.7 |
1株あたり
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | · | $0.31 | $0.30 | $0.25 | · | $0.40 | $0.05 | $-0.02 | · | $-0.15 | $0.01 | $0.14 | · | $0.52 | $0.68 | |
| Revenue / Share | · | · | $1.19 | $1.04 | $1.01 | · | $1.19 | $0.96 | $1.00 | · | $0.88 | $0.86 | $0.93 | · | $0.94 | $1.06 | |
| Cash Flow / Share | · | · | · | · | $0.04 | · | · | · | $0.02 | · | · | · | $-0.30 | · | · | · | |
| Cash / Share | $0.31 | · | $0.51 | $0.61 | $0.75 | · | $0.23 | $0.20 | $0.21 | · | $0.33 | $0.41 | $0.36 | · | $0.86 | $0.80 | |
| EPS (TTM) | $-0.08 | · | $-0.15 | $0.18 | $0.21 | · | $0.44 | $-0.06 | $-0.26 | · | $-0.72 | $-0.71 | $-0.56 | · | $-0.22 | $0.01 |
バリュエーション(TTM)
| 指標 | トレンド | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61M | · | $58M | $58M | $57M | · | $59M | $54M | $52M | · | $49M | $50M | $53M | · | $54M | $54M | |
| Net Income TTM | $-1M | · | $-2M | $2M | $3M | · | $6M | $-598.0K | $-3M | · | $-10M | $-10M | $-8M | · | $-3M | $108.0K | |
| Market Cap | $75M | · | $102M | $95M | $87M | · | $151M | $54M | $65M | · | $79M | $74M | $88M | · | $56M | $94M | |
| P/E | -67.0 | · | -48.7 | 37.9 | 30.1 | · | 25.0 | -65.2 | -18.4 | · | -8.1 | -7.7 | -11.6 | · | -18.7 | 694.0 | |
| P/S | 1.2 | · | 1.8 | 1.6 | 1.5 | · | 2.6 | 1.0 | 1.3 | · | 1.6 | 1.5 | 1.7 | · | 1.0 | 1.7 | |
| P/B | 19.2 | · | 23.7 | 22.7 | 24.8 | · | 27.5 | 78.7 | -196.1 | · | -38.4 | 798.1 | 46.1 | · | 7.9 | 10.3 | |
| P / Tangible Book | 21.0 | · | 25.7 | 24.7 | 27.5 | · | 29.3 | 154.8 | · | · | · | · | 55.9 | · | 8.3 | 10.6 | |
| P / Cash Flow | -151.6 | · | · | · | 145.2 | · | · | · | 209.4 | · | · | · | -22.0 | · | · | · | |
| Earnings Yield | -1.5% | · | -2.1% | 2.6% | 3.3% | · | 4.0% | -1.5% | -5.4% | · | -12.4% | -13.0% | -8.6% | · | -5.3% | 0.14% |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| 収益 | $59M | $57M | $50M | $54M | $49M |
| 営業利益率 % | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% |
| 純利益 | $-1M | $5M | $-7M | $-5M | $548.0K |
| 希薄化後EPS | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
| 指標 | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| 流動比率 | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 |
| クイックレシオ | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 |
| 指標 | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-5M | $7M | $-7M | $1M | $4M |
機関投資家(13F) 29 提出者 · $38.4M合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 4 (0 前期比) | 2 (-3 前期比) | 5 (0 前期比) | 7 (0 前期比) | +134K |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| BATTERY MANAGEMENT CORP. | $14,917,506 | 2,421,673 | 38.86% | 株式数 |
| NEA Management Company, LLC | $10,556,515 | 1,713,720 | 27.50% | 株式数 |
| VANGUARD GROUP INC | $2,312,121 | 334,605 | 6.02% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,856,334 | 301,353 | 4.84% | 株式数 |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $1,821,253 | 295,658 | 4.74% | 株式数 |
| MORGAN STANLEY | $1,450,064 | 235,400 | 3.78% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $1,318,597 | 214,058 | 3.43% | 株式数 |
| RENAISSANCE TECHNOLOGIES LLC | $856,480 | 139,039 | 2.23% | 株式数 |
| BlackRock, Inc. | $799,864 | 129,848 | 2.08% | 株式数 |
| Mink Brook Asset Management LLC | $685,842 | 111,338 | 1.79% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $470,118 | 76,300 | 1.22% | 株式数 |
| HighTower Advisors, LLC | $258,110 | 41,901 | 0.67% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $204,752 | 33,239 | 0.53% | 株式数 |
| NORTHERN TRUST CORP | $171,926 | 27,910 | 0.45% | 株式数 |
| STATE STREET CORP | $161,410 | 26,203 | 0.42% | 株式数 |
| Bank of New York Mellon Corp | $133,142 | 21,614 | 0.35% | 株式数 |
| CITADEL ADVISORS LLC | $112,697 | 18,295 | 0.29% | 株式数 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $112,241 | 18,221 | 0.29% | 株式数 |
| Mesirow Financial Investment Management, Inc. | $97,328 | 15,800 | 0.25% | 株式数 |
| MERCER GLOBAL ADVISORS INC /ADV | $78,694 | 12,775 | 0.20% | 株式数 |
| Vanguard Global Advisers, LLC | $12,893 | 2,093 | 0.03% | 株式数 |
| ACADIAN ASSET MANAGEMENT LLC | $125 | 20,523 | 0.00% | 株式数 |
| BARCLAYS PLC | $80 | 13 | 0.00% | 株式数 |
| Cambridge Investment Research Advisors, Inc. | $75 | 12,252 | 0.00% | 株式数 |
| JPMORGAN CHASE & CO | $71 | 11 | 0.00% | 株式数 |
| Cassaday & Co Wealth Management LLC | $62 | 10 | 0.00% | 株式数 |
| SBI Securities Co., Ltd. | $25 | 4 | 0.00% | 株式数 |
| FMR LLC | $5 | 1 | 0.00% | 株式数 |
| Capital Advisors, Ltd. LLC | $0 | 48 | 0.00% | 株式数 |
アクティビストおよび5%超のオーナー 9保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図(アクティビストの保有、取締役会キャンペーン、M&A)を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| New Enterprise Associates 14, L.P., NEA Partners 14, L.P., NEA 14 GP, LTD, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Mohamad Makhzoumi, Scott D. Sandell ×2 提出書類 | 2024年5月6日 | · | 初回提出 | · | SEC |
| Norman H. Pessin, Brian Pessin ×2 提出書類 | 2017年8月8日 | · | 初回提出 | 受動的投資 | SEC |
| PAR Investment Partners, L.P., PAR Group, L.P., PAR Capital Management, Inc., Arthur G. Epker, III ×4 提出書類 | 2016年10月28日 | · | 初回提出 | · | SEC |
| Joel Ackerman ×2 提出書類 | 2015年3月23日 | · | 初回提出 | 受動的投資 | SEC |
| Ronnie Morris ×2 提出書類 | 2015年3月23日 | · | 初回提出 | 受動的投資 | SEC |
| Battery Ventures IX, L.P., Battery Investment Partners IX, LLC, Battery Partners IX, LLC, Battery Management Corp., Scott R. Tobin, Thomas J. Crotty, Richard D. Frisbie, Kenneth P Lawler, R. David Tabors, Roger H. Lee, Neeraj Agrawal, Michael M. Brown, Jesse Feldman ×4 提出書類 | 2015年3月16日 | · | 初回提出 | 受動的投資 | SEC |
| 未開示の報告者 | 2007年5月29日 | · | 初回提出 | · | SEC |
| Manuel Hidalgo. | 2007年1月18日 | · | 初回提出 | 受動的投資 | SEC |
| 未開示の報告者 | 2007年1月11日 | · | 初回提出 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 18 人のインサイダー · 7人の役員 · 11人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Robert Lawrence Brainin | CEO | 2025年7月16日 A | · | 0 | 0 | $0 |
| Ronnie Morris | CEO | 2023年3月17日 P | 858,878 | 0 | 0 | $0 |
| CHAMPIONS SPORTS INC | Chairman, President and CEO | 2004年10月11日 P | 9,548,000 | 0 | 0 | $0 |
| Mark Schonau | Accting PEO and CFO | 2010年7月21日 A | 8,526 | 0 | 0 | $0 |
| Brady Davis | President | 2023年10月9日 A | · | 0 | 0 | $0 |
| Douglas D Burkett | President | 2008年10月3日 P | · | 0 | 0 | $0 |
| David Barry Miller | Vice President, Finance | 2016年7月21日 D | · | 0 | 0 | $0 |
| Philip P. Breitfeld | 取締役 | 2025年11月5日 A | 5,717 | 0 | 0 | $0 |
| Daniel Newman Mendelson | 取締役 | 2025年11月5日 A | 198,625 | 0 | 0 | $0 |
| David Sidransky | 取締役 | 2025年11月5日 A | 767,043 | 0 | 0 | $0 |
| Joel Ackerman | 取締役 | 2025年11月5日 A | 1,056,539 | 0 | 0 | $0 |
| Scott R. Tobin | 取締役 | 2025年11月5日 A | 30,000 | 0 | 0 | $0 |
| Abba David Poliakoff | 取締役 | 2021年1月19日 M | 81,274 | 0 | 0 | $0 |
| Arthur G Epker III | 取締役 | 2014年10月13日 A | · | 0 | 0 | $0 |
| Ana Stancic | 取締役 | 2011年7月14日 A | · | 0 | 0 | $0 |
| Michael M. Brown | 10%オーナー | 2013年1月28日 A | 16,031,040 | 0 | 0 | $0 |
| James Martell | · | 2012年1月6日 G | 1,784,828 | 0 | 0 | $0 |
| Durwood Settles | · | 2007年1月15日 A | · | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー;純額=公開市場のP/Sのみ
ETF保有状況 3のETFが保有
ウェイトは直接株式保有(N-PORT)のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
CSBR アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
同業他社比較(GICSサブインダストリー) 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | · |
| NAUT | $247M | -4.1 | · | · | -34.9% | · |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | · |
| SEER | · | -1.4 | 17.0% | · | · | · |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| HYFT | · | · | · | -89.7% | -78.9% | 58.8% |
| CIRC | · | · | · | · | · | · |
| RPID | · | -2.8 | 19.7% | -140.3% | -107.4% | · |
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | · |
トレードシグナル エントリー価格とリスク/リワード比率を伴う最近の売買シグナル
現在オープンシグナルはありません — カードは塗りつぶされておらず、それが正直なところです。
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。